Affiliations: [a] Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China | [b] Department of Digestive Disease, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China | [c] Department of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China | [d] Department of Translational Medicine Center, Zhengzhou Center Hospital, Zhengzhou, Henan, China
Correspondence:
[*]
Corresponding authors:
Xinguang Cao, Department of
Digestive Disease, The First Affiliated Hospital of Zhengzhou
University, 1 Jianshe, Road, Zhengzhou 450002, Henan, China.
Tel.: +86 0371 66295532; E-mail: [email protected];
Hong Zong, Department of Oncology, The First Affiliated Hospital of
Zhengzhou University, Zhengzhou 450052, Henan, China.
Tel.: +86 0371 66295532; E-mail: [email protected]
Abstract: BACKGROUND: This study was aimed to investigating the frequency of
Anaplastic lymphoma kinase (ALK) alterations in patients with gastric signet
ring cell carcinoma (SRC) and the correlations between ALK alterations and
the clinical-pathological features. METHODS: The expression of ALK protein was first determined in
paraffin-embedded tissue specimens (FFPE) from 177 pathologically confirmed
SRC patients by Ventana Immunohistochemistry (IHC). Then patients with ALK
positive detected by IHC were assayed in ALK rearrangement by
Fluorescence in Situ Hybridization (FISH). RESULTS: We assessed 4 of 177 cases (2.3%) as positive by IHC. 3
of the 4 patients had T4 tumors and positive nodal status, and 1 of them had
metastasis. All of them were HER2 negative. All of the 4 patients were
positive for ALK rearrangement using the standard criteria of FISH. COUCLUSION: Our analysis showed that about 2.3% of Chineses SRC
patients treated in our hospital were ALK positive. Ventana IHC and FISH
were both of the reliable approaches in SRC patients. Patients with ALK
positive seemed to have deep infiltrated and positive lymph nodes and HER2
negative.
Keywords: Anaplastic lymphoma kinase (ALK), signet ring cell carcinoma (SRC), gastric cancer
